Executive Summary
The pharmacy project in the medical and health sector in Egypt targets a promising market opportunity. With an investment of ١,٥٠٠,٠٠٠ EGP, it achieves a Net Present Value of ٢١٤,٨٢٩ EGP, an Internal Rate of Return of ٢١٪, and a payback period of 3.1 years.
| Indicator | Value |
|---|---|
| Initial Investment | ١,٥٠٠,٠٠٠ EGP |
| First Year Revenue | ٣,٠٠٠,٠٠٠ EGP |
| Annual Growth (CAGR) | ١٠٪ |
| Net Margin (Y1) | ٥٪ |
| Return on Investment (Avg.) | ١٥٪ annually |
| Net Present Value (NPV) | ٢١٤,٨٢٩ EGP |
| Internal Rate of Return (IRR) | ٢١٪ |
| Profitability Index (PI) | ١ |
| Payback Period | ٣ years |
| Break-even Year | Year ٤ |
| Expected NPV (Probability-Weighted) | ٢٤١,٧٣٤ EGP |
Assumptions and Basis
The figures in this study are based on project data, the nature of the medical and health sector in Egypt, and local market indicators, according to the following assumptions:
| Assumption | Value |
|---|---|
| Initial Capital | ١,٥٠٠,٠٠٠ EGP |
| First Year Revenue | ٣,٠٠٠,٠٠٠ EGP |
| Annual Growth | ١٠٪ |
| Cost of Goods Sold (COGS) | ٦٠٪ of Revenue |
| Operating Expenses | ٢٥٪ of Revenue |
| Tax/Zakat | ١٠٪ |
| Discount Rate (WACC) | ١٥٪ |
| Study Horizon | ٥ years |
Basis of Assumptions: Based on pharmacy sector standards in Egypt
Project Description and Opportunity
The project aims to establish a pharmacy in Egypt, where a wide range of medicines and health products will be provided. The business model will be based on selling products directly to customers.
Market and Demand Study
The Egyptian pharmacy market is continuously growing, with increasing demand for medicines and health products. The main driver for this growth is the increasing population and rising health awareness.
Market Sizing (TAM / SAM / SOM)
Market size was estimated using a qualitative sizing methodology, taking into account population size and demand for medicines.
| Level | Annual Size | Description |
|---|---|---|
| TAM — Total Available Market | 100.0 million EGP | Total serviceable demand |
| SAM — Serviceable Available Market | 20.0 million EGP | The portion your model can reach |
| SOM — Serviceable Obtainable Market | 5.0 million EGP | Your realistic early share |
Basis of Sizing: Sizing based on population size and demand for medicines
Unit Economics
Measures the profitability of each sales unit/customer — the most accurate feasibility indicator:
| Unit Indicator | Value |
|---|---|
| Sales Unit | Sales Unit |
| Average Price/Revenue per Unit | ٥٠ EGP |
| Customer Acquisition Cost (CAC) | ٢٠ EGP |
| Customer Lifetime Value (LTV) | ٥٠٠ EGP |
| LTV/CAC Ratio | ٢٥× (Healthy) |
| Contribution Margin | ٢٠٪ |
Competitive Analysis
Competition in the Egyptian pharmacy market is high, with many large and small pharmacies. However, differentiation from competitors will be achieved by offering high-quality service and product diversity.
Market Entry and Pricing Strategy
The entry plan will begin with establishing the pharmacy in a strategic location, followed by marketing the pharmacy through social media and print advertising.
Capacity and Operations
Production capacity will reach 500 sales units in the first month.
Daily operations will be carried out by a team of pharmacists and technicians, focusing on providing high-quality service to customers.
The technical aspects of the project will include the use of a pharmacy management system to improve work efficiency.
Projected Income Statement (5 Years)
| Item \ Year | Y1 | Y2 | Y3 | Y4 | Y5 |
|---|---|---|---|---|---|
| Revenue | ٣,٠٠٠,٠٠٠ EGP | ٣,٣٠٠,٠٠٠ EGP | ٣,٦٣٠,٠٠٠ EGP | ٣,٩٩٣,٠٠٠ EGP | ٤,٣٩٢,٣٠٠ EGP |
| Cost of Sales | (١,٨٠٠,٠٠٠ EGP) | (١,٩٨٠,٠٠٠ EGP) | (٢,١٧٨,٠٠٠ EGP) | (٢,٣٩٥,٨٠٠ EGP) | (٢,٦٣٥,٣٨٠ EGP) |
| Gross Profit | ١,٢٠٠,٠٠٠ EGP | ١,٣٢٠,٠٠٠ EGP | ١,٤٥٢,٠٠٠ EGP | ١,٥٩٧,٢٠٠ EGP | ١,٧٥٦,٩٢٠ EGP |
| Operating Expenses | (٧٥٠,٠٠٠ EGP) | (٨٢٥,٠٠٠ EGP) | (٩٠٧,٥٠٠ EGP) | (٩٩٨,٢٥٠ EGP) | (١,٠٩٨,٠٧٥ EGP) |
| EBITDA | ٤٥٠,٠٠٠ EGP | ٤٩٥,٠٠٠ EGP | ٥٤٤,٥٠٠ EGP | ٥٩٨,٩٥٠ EGP | ٦٥٨,٨٤٥ EGP |
| Tax | (١٥,٠٠٠ EGP) | (١٩,٥٠٠ EGP) | (٢٤,٤٥٠ EGP) | (٢٩,٨٩٥ EGP) | (٣٥,٨٨٥ EGP) |
| Net Profit | ١٣٥,٠٠٠ EGP | ١٧٥,٥٠٠ EGP | ٢٢٠,٠٥٠ EGP | ٢٦٩,٠٥٥ EGP | ٣٢٢,٩٦١ EGP |
| Net Margin | ٥٪ | ٥٪ | ٦٪ | ٧٪ | ٧٪ |
Investment Cost Structure
| Item | Cost | Percentage |
|---|---|---|
| Construction Cost | ٣٠٠,٠٠٠ EGP | ٢٠٪ |
| Medicine Cost | ٤٥٠,٠٠٠ EGP | ٣٠٪ |
| Staff Cost | ٣٠٠,٠٠٠ EGP | ٢٠٪ |
| Marketing Cost | ٢٢٥,٠٠٠ EGP | ١٥٪ |
| Other Costs | ٢٢٥,٠٠٠ EGP | ١٥٪ |
Cash Flow and Break-even Point
| Year | Operating Cash Flow | Cumulative Cash Flow |
|---|---|---|
| Year ١ | ٤٣٥,٠٠٠ EGP | -١,٠٦٥,٠٠٠ EGP |
| Year ٢ | ٤٧٥,٥٠٠ EGP | -٥٨٩,٥٠٠ EGP |
| Year ٣ | ٥٢٠,٠٥٠ EGP | -٦٩,٤٥٠ EGP |
| Year ٤ | ٥٦٩,٠٥٥ EGP | ٤٩٩,٦٠٥ EGP |
| Year ٥ | ٦٢٢,٩٦١ EGP | ١,١٢٢,٥٦٦ EGP |
Estimated break-even point at annual revenue ≈ ٢,٦٢٥,٠٠٠ EGP (~٨٨٪ of first-year revenue), with a contribution margin of ٤٠٪. Cumulative cash break-even in Year ٤.
Funding Structure
| Funding Source | Percentage | Amount |
|---|---|---|
| Equity | ٦٠٪ | ٩٠٠,٠٠٠ EGP |
| Debt Financing (١٢٪ interest) | ٤٠٪ | ٦٠٠,٠٠٠ EGP |
Sensitivity Analysis (Revenue × Operations)
Impact of simultaneous changes in revenue and costs on Net Present Value:
| Revenue \ Operations | −10٪ | −5٪ | Base | +5٪ | +10٪ |
|---|---|---|---|---|---|
| −20٪ | ٧٥٢,٩١٧ EGP | ٣٢٢,٤٤٧ EGP | -١٠٨,٠٢٤ EGP | -٥٤٧,٠٦٥ EGP | -١,٠٢١,٦٩٩ EGP |
| −10٪ | ١,٠٢١,٩٦١ EGP | ٥٣٧,٦٨٢ EGP | ٥٣,٤٠٣ EGP | -٤٣٣,٧١٢ EGP | -٩٦١,٩١٢ EGP |
| Base | ١,٢٩١,٠٠٥ EGP | ٧٥٢,٩١٧ EGP | ٢١٤,٨٢٩ EGP | -٣٢٣,٢٥٩ EGP | -٩٠٢,١٢٤ EGP |
| +10٪ | ١,٥٦٠,٠٤٩ EGP | ٩٦٨,١٥٢ EGP | ٣٧٦,٢٥٥ EGP | -٢١٥,٦٤١ EGP | -٨٤٢,٣٣٧ EGP |
| +20٪ | ١,٨٢٩,٠٩٣ EGP | ١,١٨٣,٣٨٨ EGP | ٥٣٧,٦٨٢ EGP | -١٠٨,٠٢٤ EGP | -٧٨٢,٥٤٩ EGP |
Scenario Analysis
| Scenario | Probability | NPV | Assessment |
|---|---|---|---|
| Pessimistic | ٢٥٪ | -٣٢٣,٢٥٩ EGP | Not feasible |
| Base | ٥٠٪ | ٢١٤,٨٢٩ EGP | Feasible |
| Optimistic | ٢٥٪ | ٨٦٠,٥٣٥ EGP | Feasible |
Expected Present Value (Weighted): ٢٤١,٧٣٤ EGP.
Risk Analysis and Management
| Risk | Probability | Impact | Mitigation |
|---|---|---|---|
| Risk of failure to obtain licenses | Low | High | Ensuring adherence to legal procedures |
| Competition risk | High | High | Continuous improvement of customer service |
| Economic changes risk | Medium | High | Diversification of revenue sources |
| Technical errors risk | Low | Low | Continuous training of employees |
Organizational Structure and Team
The organizational structure will include a general manager and a number of pharmacists and technicians.
Legal and Regulatory Aspects
Licenses and compliance will be obtained from the Egyptian Ministry of Health.
Expansion and Sustainability Plan
Expansion will be achieved by opening new branches in urban areas.
Environmental, Social, and Governance (ESG) Impact
Environmental impact will be improved through the use of eco-friendly materials.
Conclusions and Recommendations
The conclusion is that the pharmacy project in Egypt is considered a profitable and feasible project.
Frequently Asked Questions
How much does it cost to establish a pharmacy in Egypt?
1,500,000 EGP
How much profit does a pharmacy project make in Egypt?
3,000,000 EGP in the first year
What are the licenses for establishing a pharmacy in Egypt?
Licenses from the Egyptian Ministry of Health
Is a pharmacy project profitable in Egypt?
Yes, according to the study
How many pharmacies are there in Egypt?
More than 10,000 pharmacies
What is the size of the pharmacy market in Egypt?
100,000,000 EGP
Sources and Disclaimer
- Egyptian Ministry of Health
- Egyptian Chamber of Commerce
- Private market studies
Disclaimer: This is a guiding study that provides financial analysis according to approved sector standards; verify the figures locally according to your project's reality before any investment decision.
